Top

Cancer Cell International

Published in:

Open Access 01-12-2021 | Hepatocellular Carcinoma | Review

Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis

Authors: Sha Yang, Huapeng Lin, Jianning Song

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Several treatments are available for treatment of early and very early-stage Hepatocellular Carcinoma, also known as small Hepatocellular Carcinoma (SHCC). However, there is no consensus with regards to the efficacies of these methods. We aimed at identifying the most effective initial treatment strategy for SHCC through Bayesian network meta-analyses.

Methods

Studies published between January, 2010, and February, 2021 were searched in EMBASE, Cochrane Library, PubMed and Web of science databases, and conference proceedings for trials. The included studies reported the survival outcomes of very early and early Hepatocellular Carcinoma patients subjected to radiofrequency ablation (RFA), microwave ablation (MWA), surgical resection (SR), transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI), minimally invasive liver surgery (MIS), stereotactic body radiotherapy (SBRT) and cryoablation (CA). Then, data were extracted from studies that met the inclusion criteria. Patient survival data were retrieved from the published Kaplan–Meier curves and pooled. A Bayesian random-effects model was used to combine direct and indirect evidence.

Results

A total of 2058 articles were retrieved and screened, from which 45 studies assessing the efficacies of 8 different treatments in 11,364 patients were selected. The included studies had high methodological quality. Recurrence free survival* (progression/recurrence/relapse/disease/tumor-free survival were combined and redefined as RFS*) and overall survival (OS) outcomes were highest in MIS-treated patients (HR 0·57, 95% confidence intervals [CI] 0·38–0·85; HR 0.48,95% CI 0.36–0.64, respectively), followed by SR-treated patients (HR 0.60, 95% CI 0.50–0.74; HR 0.62, 95% CI 0.55–0.72, respectively). TACE was highly efficacious (58.9%) at decreasing the rates of major complications. Similar findings were obtained through sensitivity analysis, and in most of the prognostic subgroups.

Conclusions

MIS and SR exhibited the highest clinical efficacies, however, they were associated with higher rates of complications. Ablation is effective in small tumors, whereas SBRT is a relatively promising treatment option for SHCC. More well-designed, large-scale randomized controlled trials should be performed to validate our findings.

Available only for authorised users

International Agency for Research on Cancer, World Health Organization. Cancer today. https://gco.iarc.fr/today/home.

World Health Organization. Projections of mortality and causes of death, 2016 to 2060. http://www.who.int/healthinfo/global_burden_disease/projections/en/.

Centers for Disease Control and Prevention, National Center for Health Statistics. Trends in liver cancer mortality among adults aged 25 and over in the United States, 2000 2016. July 2018. https://www.cdc.gov/nchs/products/databriefs/ db314.htm.

Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a multicenter study. Clin Gastroenterol Hepatol. 2018;16(6):955–64. https://doi.org/10.1016/j.cgh.2017.11.037 (Epub 2017 Nov 23).CrossRefPubMed

Organ Procurement and Transplantation Network. Policies. 2020. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236. doi: https://doi.org/10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. Erratum in: J Hepatol. 2019 Apr;70(4):817.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50. https://doi.org/10.1002/hep.29913.CrossRefPubMed

DelPiccolo N, Onkendi E, Nguyen J, Patel S, Asbun HJ, Burns J, Croome K, Obi JR, Stauffer JA. Outcomes of minimally invasive versus open major hepatic resection. J Laparoendosc Adv Surg Tech A. 2020;30(7):790–6. https://doi.org/10.1089/lap.2019.0615 (Epub 2020 Apr 23).CrossRefPubMed

Bauschke A, Kissler H, Settmacher U. Minimal-invasive Leberchirurgie [Minimally invasive liver surgery]. Chirurg. 2021;92(9):853–60. https://doi.org/10.1007/s00104-021-01380-2 (Epub 2021 Mar 30).CrossRefPubMed

10.

Deng ZC, Jiang WZ, Tang XD, Liu SH, Qin L, Qian HX. Laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma in 157 patients: a case controlled study with propensity score matching at two Chinese centres. Int J Surg. 2018;56:203–7. https://doi.org/10.1016/j.ijsu.2018.06.026 (Epub 2018 Jun 20).CrossRefPubMed

11.

Tsai KY, Chen HA, Wang WY, Huang MT. Long-term and short-term surgical outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma: might laparoscopic approach be better in early HCC? Surg Endosc. 2019;33(4):1131–9. https://doi.org/10.1007/s00464-018-6372-0 (Epub 2018 Jul 24).CrossRefPubMed

12.

Brandi G, Rizzo A, Dall Olio FG, Felicani C, Ercolani G, Cescon M, Frega G, Tavolari S, Palloni A, De Lorenzo S, Abbati F, Mollica V, Ricci AD, Serra C. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective, single-center experience. Inter J Hyperthermia. 2020;37(1):479–85. https://doi.org/10.1080/02656736.2020.1763484.CrossRef

13.

Chang YJ, Chen LJ, Chang YJ, Chen PD. Population-based matching comparison between radiofrequency ablation and percutaneous ethanol or acetic acid injection for hepatocellular carcinoma. Eur J Surg Oncol. 2020;46(9):1703–10. https://doi.org/10.1016/j.ejso.2020.04.039 (Epub 2020 Apr 25).CrossRefPubMed

14.

Feng J, Qi X, Guo X, Qi X. Early-stage hepatocellular carcinoma: radiofrequency ablation or resection? Am J Gastroenterol. 2019;114(2):359. https://doi.org/10.14309/ajg.0000000000000131.CrossRefPubMed

15.

Mukund A, Vats P, Jindal A, Patidar Y, Sarin SK. Early hepatocellular carcinoma treated by radiofrequency ablation-mid- and long-term outcomes. J Clin Exp Hepatol. 2020;10(6):563–73. https://doi.org/10.1016/j.jceh.2020.04.016 (Epub 2020 May 4).CrossRefPubMedPubMedCentral

16.

Weinstein JL, Ahmed M. Percutaneous ablation for hepatocellular carcinoma. AJR Am J Roentgenol. 2018;210(6):1368–75. https://doi.org/10.2214/AJR.17.18695 (Epub 2018 Apr 27).CrossRefPubMed

17.

Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: current evidence and future directions. World J Gastroenterol. 2019;25(32):4614–28. https://doi.org/10.3748/wjg.v25.i32.4614.CrossRefPubMedPubMedCentral

18.

Kalra N, Gupta P, Gorsi U, Bhujade H, Chaluvashetty SB, Duseja A, Singh V, Dhiman RK, Chawla YK, Khandelwal N. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience. Cardiovasc Intervent Radiol. 2019;42(4):584–90. https://doi.org/10.1007/s00270-019-02164-2 (Epub 2019 Jan 29).CrossRefPubMed

19.

Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T, Takawa M, Nagamatsu H, Imai Y. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol. 2018;3(2018):4756147. https://doi.org/10.1155/2018/4756147.CrossRef

20.

Yu J, Yu XL, Han ZY, Cheng ZG, Liu FY, Zhai HY, Mu MJ, Liu YM, Liang P. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut. 2017;66(6):1172–3. https://doi.org/10.1136/gutjnl-2016-312629 (Epub 2016 Nov 24).CrossRefPubMed

21.

Liu W, Zheng Y, He W, Zou R, Qiu J, Shen J, Yang Z, Zhang Y, Wang C, Wang Y, Zuo D, Li B, Yuan Y. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment Pharmacol Ther. 2018;48(6):671–81. https://doi.org/10.1111/apt.14929 (Epub 2018 Jul 31).CrossRefPubMed

22.

Kang TW, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: refining the current status based on emerging evidence and future perspectives. World J Gastroenterol. 2018;24(47):5331–7. https://doi.org/10.3748/wjg.v24.i47.5331.CrossRefPubMedPubMedCentral

23.

Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol. 2019;29:654–62. https://doi.org/10.1007/s00330-018-5617-6.CrossRefPubMed

24.

Glazer DI, Tatli S, Shyn PB, Vangel MG, Tuncali K, Silverman SG. Percutaneous image-guided cryoablation of hepatic tumors: single-center experience with intermediate to long-term outcomes. AJR Am J Roentgenol. 2017;209(6):1381–9. https://doi.org/10.2214/AJR.16.17582 (Epub 2017 Sep 27).CrossRefPubMedPubMedCentral

25.

Xu Y, Shen Q, Liu P, Xu Z, Wu P, Lu Z, Chen Y, Huang B, Qian G. Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes. Eur Radiol. 2017;27(9):3877–87. https://doi.org/10.1007/s00330-017-4740-0 (Epub 2017 Feb 10).CrossRefPubMed

26.

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604. https://doi.org/10.1038/s41575-019-0186-y.CrossRefPubMedPubMedCentral

27.

Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol. 2020;145:63–70. https://doi.org/10.1016/j.radonc.2019.12.004 (Epub 2020 Jan 7).CrossRefPubMed

28.

Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135–44. https://doi.org/10.1016/j.radonc.2018.12.005 (Epub 2018 Dec 31).CrossRefPubMed

29.

Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T, Miriplatin TACE Study Group. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol. 2018;53(2):281–90. https://doi.org/10.1007/s00535-017-1374-6 (Epub 2017 Aug 1).CrossRefPubMed

30.

Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–16. https://doi.org/10.1002/hep.28453 (Epub 2016 Mar 7).CrossRefPubMed

31.

Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J, Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9. https://doi.org/10.1016/S0140-6736(02)08649-X.CrossRefPubMed

32.

Heinecke A, Tallarita M, De Iorio M. Bayesian splines versus fractional polynomials in network meta-analysis. BMC Med Res Methodol. 2020;20(1):261. https://doi.org/10.1186/s12874-020-01113-9.CrossRefPubMedPubMedCentral

33.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https://doi.org/10.1186/2046-4053-4-1.CrossRefPubMedPubMedCentral

34.

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84. https://doi.org/10.7326/M14-2385.CrossRefPubMed

35.

Wells GA, Shea B, O Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta- analyses. 2000. www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf. Accessed 27 Jul 2015.

36.

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.CrossRefPubMedPubMedCentral

37.

Balieiro Anastacio da Costa AA, Baiocchi G, Guimarães APG. Progression-free survival in the ICON8 trial. Lancet. 2020;396(10253):756–7. https://doi.org/10.1016/S0140-6736(20)31176-4 (Erratum in: Lancet. 2020 Oct 3;396(10256):e56).CrossRefPubMed

38.

Shamsaeefar A, Nikeghbalian S, Kazemi K, Gholami S, Motazedian N, Motazedian N, Fallahzadeh ME, Moini M, Gramizadeh B, Malekhosseini SA. Predictors of tumor-free survival after liver transplant in patient with hepatocellular carcinoma. Exp Clin Transplant. 2015;13(Suppl 1):139–44.PubMed

39.

Cooper K, Tappenden P, Cantrell A, Ennis K. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. Br J Cancer. 2020;123(11):1686–96. https://doi.org/10.1038/s41416-020-01050-w (Epub 2020 Sep 11).CrossRefPubMedPubMedCentral

40.

Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98–110. https://doi.org/10.1002/jrsm.1044.CrossRefPubMedPubMedCentral

41.

Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11(5):956–64. https://doi.org/10.1111/j.1524-4733.2008.00347.x (Epub 2008 May 16).CrossRefPubMed

42.

Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7–8):932–44. https://doi.org/10.1002/sim.3767.CrossRefPubMed

43.

Vietti Violi N, Duran R, Guiu B, Cercueil JP, Aubé C, Digklia A, Pache I, Deltenre P, Knebel JF, Denys A. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3(5):317–25. https://doi.org/10.1016/S2468-1253(18)30029-3 (Epub 2018 Mar 2).CrossRefPubMed

44.

Kamal A, Elmoety AAA, Rostom YAM, Shater MS, Lashen SA. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol. 2019;10(3):562–71. https://doi.org/10.21037/jgo.2019.01.34.CrossRefPubMedPubMedCentral

45.

Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, Nabeel M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc. 2014;28(12):3429–34. https://doi.org/10.1007/s00464-014-3617-4 (Epub 2014 Jun 17).CrossRefPubMed

46.

Du S, Yang JZ, Chen J, Zhou WG, Sun YY. Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: a multiple centers retrospective cohort study with propensity score matching. PLoS ONE. 2020;15(1): e0227242. https://doi.org/10.1371/journal.pone.0227242.CrossRefPubMedPubMedCentral

47.

Cillo U, Noaro G, Vitale A, Neri D, D’Amico F, Gringeri E, Farinati F, Vincenzi V, Vigo M, Zanus G, HePaTIC Study Group. Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. HPB (Oxford). 2014;16(11):979–86. https://doi.org/10.1111/hpb.12264 (Epub 2014 Apr 18).CrossRef

48.

Ghweil A, Osman H. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. Hepatol Int. 2019;13(1):1–266.CrossRef

49.

Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS ONE. 2013;8(10): e76119. https://doi.org/10.1371/journal.pone.0076119.CrossRefPubMedPubMedCentral

50.

Vogl TJ, Farshid P, Naguib NN, Zangos S, Bodelle B, Paul J, Mbalisike EC, Beeres M, Nour-Eldin NE. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. Abdom Imaging. 2015;40(6):1829–37. https://doi.org/10.1007/s00261-015-0355-6.CrossRefPubMed

51.

Potretzke TA, Ziemlewicz TJ, Hinshaw JL, Lubner MG, Wells SA, Brace CL, Agarwal P, Lee FT Jr. Microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: a comparison of efficacy at a single center. J Vasc Interv Radiol. 2016;27(5):631–8. https://doi.org/10.1016/j.jvir.2016.01.136 (Epub 2016 Mar 24).CrossRefPubMedPubMedCentral

52.

Ding J, Jing X, Liu J, Wang Y, Wang F, Wang Y, Du Z. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol. 2013;82(9):1379–84. https://doi.org/10.1016/j.ejrad.2013.04.025 (Epub 2013 May 28).CrossRefPubMed

53.

Xu Y, Shen Q, Wang N, Wu PP, Huang B, Kuang M, Qian GJ. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. Chin J Cancer. 2017;36(1):14. https://doi.org/10.1186/s40880-017-0183-x.CrossRefPubMedPubMedCentral

54.

Santambrogio R, Chiang J, Barabino M, Meloni FM, Bertolini E, Melchiorre F, Opocher E. Comparison of laparoscopic microwave to radiofrequency ablation of small hepatocellular carcinoma (≤3 cm). Ann Surg Oncol. 2017;24(1):257–63. https://doi.org/10.1245/s10434-016-5527-2 (Epub 2016 Aug 31).CrossRefPubMed

55.

Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802. https://doi.org/10.1016/j.jhep.2012.05.007 (Epub 2012 May 23).CrossRefPubMed

56.

Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, Wang K, Pan H. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(1):193–200. https://doi.org/10.1111/jgh.12441.CrossRefPubMed

57.

Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, Kao WY, Huo TI, Huang YH, Su YH, Lin HC, Lee SD, Wu JC. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9(1):79–86. https://doi.org/10.1016/j.cgh.2010.08.018 (Epub 2010 Sep 8).CrossRefPubMed

58.

Wong KM, Yeh ML, Chuang SC, Wang LY, Lin ZY, Chen SC, Tsai JF, Wang SN, Kuo KK, Dai CY, Yu ML, Lee KT, Chuang WL. Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma. Indian J Gastroenterol. 2013;32(4):253–7. https://doi.org/10.1007/s12664-012-0225-x (Epub 2012 Aug 30).CrossRefPubMed

59.

Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56(2):412–8. https://doi.org/10.1016/j.jhep.2011.05.020 (Epub 2011 Jul 12).CrossRefPubMed

60.

Imai K, Beppu T, Chikamoto A, Doi K, Okabe H, Hayashi H, Nitta H, Ishiko T, Takamori H, Baba H. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43(8):853–64. https://doi.org/10.1111/hepr.12035 (Epub 2013 Jan 2).CrossRefPubMed

61.

Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, Kim HC, Lee JM, Chung JW, Yi NJ, Lee KW, Suh KS, Lee HS. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology. 2014;271(3):909–18. https://doi.org/10.1148/radiol.13131760 (Epub 2014 Feb 8).CrossRefPubMed

62.

Hocquelet A, Balageas P, Laurent C, Blanc JF, Frulio N, Salut C, Cassinotto C, Saric J, Possenti L, Bernard PH, Montaudon M, Trillaud H. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria: a study of 281 Western patients. Int J Hyperthermia. 2015;31(7):749–57. https://doi.org/10.3109/02656736.2015.1068382 (Epub 2015 Sep 12).CrossRefPubMed

63.

Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. Ann Surg. 2016;263(3):538–45. https://doi.org/10.1097/SLA.0000000000001178 (Erratum.In:AnnSurg.2016May;263(5):e77).CrossRefPubMed

64.

Guan TP, Fang CH, Yang J, Xiang N, Chen QS, Zhong SZ. A Comparison between three-dimensional visualization guided hepatectomy and ultrasonography guided radiofrequency ablation in the treatment of small hepatocellular carcinoma within the milan criteria. Biomed Res Int. 2016;2016:8931732. https://doi.org/10.1155/2016/8931732 (Epub 2016 May 12. Retraction in: Biomed Res Int. 2017;2017:8014852).CrossRefPubMedPubMedCentral

65.

Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, Yuen J, Poon RTP, Fan ST, Lo CM. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104(13):1775–84. https://doi.org/10.1002/bjs.10677 (Epub 2017 Nov 1).CrossRefPubMed

66.

Lee HW, Lee JM, Yoon JH, Kim YJ, Park JW, Park SJ, Kim SH, Yi NJ, Suh KS. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res. 2018;94(2):74–82. https://doi.org/10.4174/astr.2018.94.2.74 (Epub 2018 Jan 30).CrossRefPubMedPubMedCentral

67.

Santambrogio R, Bruno S, Kluger MD, Costa M, Salceda J, Belli A, Laurent A, Barabino M, Opocher E, Azoulay D, Cherqui D. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma. Dig Liver Dis. 2016;48(2):189–96. https://doi.org/10.1016/j.dld.2015.11.010 (Epub 2015 Nov 23).CrossRefPubMed

68.

Oh JH, Sinn DH, Choi GS, Kim JM, Joh JW, Kang TW, Hyun D, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res. 2020;99(4):238–46. https://doi.org/10.4174/astr.2020.99.4.238 (Epub 2020 Sep 24).CrossRefPubMedPubMedCentral

69.

Hsiao CY, Hu RH, Ho CM, Wu YM, Lee PH, Ho MC. Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study. Am J Surg. 2020;220(4):958–64. https://doi.org/10.1016/j.amjsurg.2020.03.017 (Epub 2020 Mar 25).CrossRefPubMed

70.

Liang B, Yao S, Zhou J, Li Z, Liu T. Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma. J Hepatocell Carcinoma. 2018;12(5):1–7. https://doi.org/10.2147/JHC.S152202.CrossRef

71.

Di Sandro S, Benuzzi L, Lauterio A, Botta F, De Carlis R, Najjar M, Centonze L, Danieli M, Pezzoli I, Rampoldi A, Bagnardi V, De Carlis L. Single Hepatocellular Carcinoma approached by curative-intent treatment: a propensity score analysis comparing radiofrequency ablation and liver resection. Eur J Surg Oncol. 2019;45(9):1691–9. https://doi.org/10.1016/j.ejso.2019.04.023 (Epub 2019 Apr 29).CrossRefPubMed

72.

Santambrogio R, Barabino M, Bruno S, Mariani N, Maroni N, Bertolini E, Franceschelli G, Opocher E. Surgical resection vs. ablative therapies through a laparoscopic approach for hepatocellular carcinoma: a comparative study. J Gastrointest Surg. 2018;22(4):650–60. https://doi.org/10.1007/s11605-017-3648-y (Epub 2017 Dec 12).CrossRefPubMed

73.

Casaccia M, Santori G, Bottino G, Diviacco P, Andorno E. Laparoscopic resection vs laparoscopic radiofrequency ablation for the treatment of small hepatocellular carcinomas: a single-center analysis. World J Gastroenterol. 2017;23(4):653–60. https://doi.org/10.3748/wjg.v23.i4.653.CrossRefPubMedPubMedCentral

74.

Song J, Wang Y, Ma K, Zheng S, Bie P, Xia F, Li X, Li J, Wang X, Chen J. Laparoscopic hepatectomy versus radiofrequency ablation for minimally invasive treatment of single, small hepatocellular carcinomas. Surg Endosc. 2016;30(10):4249–57. https://doi.org/10.1007/s00464-015-4737-1 (Epub 2015 Dec 29).CrossRefPubMed

75.

Vitali GC, Laurent A, Terraz S, Majno P, Buchs NC, Rubbia-Brandt L, Luciani A, Calderaro J, Morel P, Azoulay D, Toso C. Minimally invasive surgery versus percutaneous radio frequency ablation for the treatment of single small (≤3 cm) hepatocellular carcinoma: a case-control study. Surg Endosc. 2016;30(6):2301–7. https://doi.org/10.1007/s00464-015-4295-6 (Epub 2015 Nov 3).CrossRefPubMed

76.

Ogiso S, Seo S, Eso Y, Yoh T, Kawai T, Okumura S, Ishii T, Fukumitsu K, Taura K, Seno H, Uemoto S. Laparoscopic liver resection versus percutaneous radiofrequency ablation for small hepatocellular carcinoma. HPB (Oxford). 2021;23(4):533–7. https://doi.org/10.1016/j.hpb.2020.08.009 (Epub 2020 Sep 7).CrossRef

77.

Chong CC, Lee KF, Chu CM, Chan AW, Yu SC, Lai PB. Laparoscopic hepatectomy (with or without robotic assistance) versus radiofrequency ablation as a minimally invasive treatment for very early-stage or early-stage hepatocellular carcinoma. Dig Surg. 2020;37(1):65–71. https://doi.org/10.1159/000497112 (Epub 2019 Mar 27).CrossRefPubMed

78.

Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–9. https://doi.org/10.1200/JCO.2015.61.4925 (Epub 2015 Nov 30).CrossRefPubMed

79.

Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, Seong J. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81–7. https://doi.org/10.1016/j.radonc.2018.12.013 (Epub 2018 Dec 31).CrossRefPubMed

80.

Sun J, Wang Q, Hong ZX, Li WG, He WP, Zhang T, Zhang AM, Fan YZ, Sun YZ, Zheng L, Duan XZ. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis. Hepatol Int. 2020;14(5):788–97. https://doi.org/10.1007/s12072-020-10088-0 (Epub 2020 Sep 4).CrossRefPubMed

81.

Nakano R, Ohira M, Kobayashi T, Ide K, Tahara H, Kuroda S, Shimizu S, Kimura T, Nagata Y, Aikata H, Chayama K, Ohdan H. Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: a propensity-matched analysis in a single institution. Surgery. 2018;164(2):219–26. https://doi.org/10.1016/j.surg.2018.03.006 (Epub 2018 May 23).CrossRefPubMed

82.

Martin AN, Wilkins LR, Das D, Johnston LE, Bauer TW, Adams RB, Zaydfudim VM. Efficacy of radiofrequency ablation versus transarterial chemoembolization for patients with solitary hepatocellular carcinoma ≤3 cm. Am Surg. 2019;85(2):150–5.CrossRefPubMed

83.

Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, Bai W, Dong Z, Lu Y, Zeng Z, Lou M, Wang H, Gao X, Chang X, An L, Qu J, Li J, Yang Y. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61(5):1579–90. https://doi.org/10.1002/hep.27548 (Epub 2015 Mar 20).CrossRefPubMed

84.

Xu J, Noda C, Erickson A, Mokkarala M, Charalel R, Ramaswamy R, Tao YU, Akinwande O. Radiofrequency ablation vs. cryoablation for localized hepatocellular carcinoma: a propensity-matched population study. Anticancer Res. 2018;38(11):6381–6. https://doi.org/10.21873/anticanres.12997.CrossRefPubMed

85.

Hu J, Chen S, Wang X, Lin N, Yang J, Wu S. Image-guided percutaneous microwave ablation versus cryoablation for hepatocellular carcinoma in high-risk locations: intermediate-term results. Cancer Manag Res. 2019;18(11):9801–11. https://doi.org/10.2147/CMAR.S227961.CrossRef

86.

Burdorf A, van der Beek AJ. To RCT or not to RCT: evidence on effectiveness of return-to-work interventions. Scand J Work Environ Health. 2016;42(4):257–9. https://doi.org/10.5271/sjweh.3577 (Epub 2016 Jun 7).CrossRefPubMed

87.

Tsoris A, Marlar CA. Use of the child pugh score in liver disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021

88.

Mokdad AA, Singal AG, Marrero JA, Zhu H, Yopp AC. Vascular invasion and metastasis is predictive of outcome in barcelona clinic liver cancer stage C hepatocellular carcinoma. J Natl Compr Canc Netw. 2017;15(2):197–204. https://doi.org/10.6004/jnccn.2017.0020.CrossRefPubMed

89.

Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, ITA.LI.CA study group. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021;41(3):585–97. https://doi.org/10.1111/liv.14735 (Epub 2020 Dec 2).CrossRefPubMed

90.

Tsochatzis E, Meyer T, O’Beirne J, Burroughs AK. Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL)—European Organisation for Research and Treatment of Cancer (EORTC) guidelines. Eur J Cancer. 2013;49(6):1509–10. https://doi.org/10.1016/j.ejca.2012.11.012 (Epub 2012 Dec 8).CrossRefPubMed

91.

Kaibori M, Yoshii K, Hasegawa K, Ariizumi S, Kobayashi T, Kamiyama T, Kudo A, Yamaue H, Kokudo N, Yamamoto M. Impact of systematic segmentectomy for small hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2020;27(6):331–41. https://doi.org/10.1002/jhbp.720 (Epub 2020 Feb 27).CrossRefPubMed

92.

Zhu GQ, Sun M, Liao WT, Yu WH, Zhou SL, Zhou ZJ, Shi YH, Fan J, Zhou J, Qiu LX, Dai Z. Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12(9):935–45. https://doi.org/10.1080/17474124.2018.1503531 (Epub 2018 Jul 25).CrossRefPubMed

93.

Ricci AD, Rizzo A, Bonucci C, Tavolari S, Palloni A, Frega G, Mollica V, Tober N, Mazzotta E, Felicani C, Serra C, Brandi G. The (Eternal) debate on microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma. In Vivo. 2020;34(6):3421–9. https://doi.org/10.21873/invivo.12181.CrossRefPubMedPubMedCentral

94.

Gui CH, Baey S, D’cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma—a meta-analysis. Eur J Surg Oncol. 2020;46(5):763–71. https://doi.org/10.1016/j.ejso.2020.01.004 (Epub 2020 Jan 7).CrossRefPubMed

95.

Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;9(10):78. https://doi.org/10.1186/1471-230X-10-78.CrossRef

96.

Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20(3):130–40. https://doi.org/10.1097/SLE.0b013e3181d823df.CrossRefPubMed

97.

Rizzo A, Frega G, Ricci AD, Palloni A, Abbati F, De Lorenzo S, Deserti M, Tavolari S, Brandi G. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis. In Vivo. 2020;34(2):479–88. https://doi.org/10.21873/invivo.11798.CrossRefPubMedPubMedCentral

98.

Lee DH, Lee JM. Recent advances in the image-guided tumor ablation of liver malignancies: radiofrequency ablation with multiple electrodes, real-time multimodality fusion imaging, and new energy sources. Korean J Radiol. 2018;19(4):545–59. https://doi.org/10.3348/kjr.2018.19.4.545 (Epub 2018 Jun 14).CrossRefPubMedPubMedCentral

99.

Imajo K, Ogawa Y, Yoneda M, Saito S, Nakajima A. A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma. J Med Ultrason (2001). 2020;47(2):265–77. https://doi.org/10.1007/s10396-019-00997-5 (Epub 2020 Jan 20).CrossRef

100.

Patel HR. Effects of cross diffusion and heat generation on mixed convective MHD flow of Casson fluid through porous medium with non-linear thermal radiation. Heliyon. 2019;5(4): e01555. https://doi.org/10.1016/j.heliyon.2019.e01555.CrossRefPubMedPubMedCentral

101.

Sparchez Z, Mocan T, Radu P, Mocan LP, Sparchez M, Leucuta DC, Al HN. Prognostic factors after percutaneous radiofrequency ablation in the treatment of hepatocellular. Carcinoma impact of incomplete ablation on recurrence and overall survival rates. J Gastrointestin Liver Dis. 2018;27(4):399–407. https://doi.org/10.15403/jgld.2014.1121.274.pro.CrossRefPubMed

102.

Facciorusso A, AbdElAziz MA, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Pusceddu S, Giacomelli L, Ambrosi A, Sacco R. Microwave ablation versus radiofrequency ablation for treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Cancers (Basel). 2020;12(12):3796. https://doi.org/10.3390/cancers12123796.CrossRefPubMedCentral

103.

Tan W, Deng Q, Lin S, Wang Y, Xu G. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2019;36(1):264–72. https://doi.org/10.1080/02656736.2018.1562571 (Epub 2019 Jan 24).CrossRefPubMed

104.

Kalra N, Gupta P, Jugpal T, Naik SS, Gorsi U, Chaluvashetty SB, Bhujade H, Duseja A, Singh V, Dhiman RK, Sandhu MS. Percutaneous cryoablation of liver tumors: initial experience from a tertiary care center in India. J Clin Exp Hepatol. 2021;11(3):305–11. https://doi.org/10.1016/j.jceh.2020.10.005 (Epub 2020 Oct 19).CrossRefPubMed

105.

Lin Y, Wen Q, Guo L, Wang H, Sui G, Sun Z. A network meta-analysis on the efficacy and prognosis of different interventional therapies for early-stage hepatocellular carcinoma. Int J Hyperthermia. 2018;35(1):450–62. https://doi.org/10.1080/02656736.2018.1507047 (Epub 2018 Oct 25).CrossRefPubMed

106.

Lan T, Chang L, Mn R, Wu L, Yuan YF. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016;95(15): e3185. https://doi.org/10.1097/MD.0000000000003185.CrossRef

107.

Wang H, Jin C, Fang L, Sun H, Cheng W, Hu S. Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review. Cost Eff Resour Alloc. 2020;10(18):1. https://doi.org/10.1186/s12962-019-0198-z.CrossRef

108.

Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. Onco Targets Ther. 2018;16(11):2865–74. https://doi.org/10.2147/OTT.S164651.CrossRef

109.

Sanuki N, Takeda A. Are head-to-head comparisons between radiofrequency ablation and stereotactic body radiotherapy really necessary for localized hepatocellular carcinoma? J Clin Oncol. 2018;36(24):2563–4. https://doi.org/10.1200/JCO.2018.78.2805 (Epub 2018 Jun 26).CrossRefPubMed

110.

Qi X, Tang Y, An D, Bai M, Shi X, Wang J, Han G, Fan D. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2014;48(5):450–7. https://doi.org/10.1097/MCG.0000000000000008.CrossRefPubMed

111.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7(8):16. https://doi.org/10.1186/1745-6215-8-16.CrossRef

112.

Shrier I, Boivin JF, Steele RJ, Platt RW, Furlan A, Kakuma R, Brophy J, Rossignol M. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166(10):1203–9. https://doi.org/10.1093/aje/kwm189; (Epub 2007 Aug 21).CrossRefPubMed

Title: Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis
Authors: Sha Yang
Huapeng Lin
Jianning Song
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02365-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

DDX52 knockdown inhibits the growth of prostate cancer cells by regulating c-Myc signaling

Regulator of cullins-1 (ROC1) negatively regulates the Gli2 regulator SUFU to activate the hedgehog pathway in bladder cancer

Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma

Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism‐related genes

LINC00514 upregulates CCDC71L to promote cell proliferation, migration and invasion in triple‐negative breast cancer by sponging miR-6504-5p and miR-3139

Signaling pathways of EBV-induced oncogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer